Pele Chong obtained his B.S. degree in September 1978 and his Ph.D. degree in February 1983 from the Department of Biochemistry, University of Alberta, Edmonton, AB, Canada. He was trained as a protein chemist and specialized in peptide synthesis for protein structure and function studies. Chong then worked on the recombinant subunit vaccine development for 2 years as an MRC Postdoctoral Fellow at the Department of Pathology, University of British Columbia, Vancouver, BC, Canada. Chong then moved to Toronto and spent 15 years at the Connaught Laboratory Limited (now called Sanofi Pasteur) in human vaccine research and development. During his tenure there as a Research Scientist (July 1985) and Director (July 1994), Chong had developed two human vaccines, ProHibit against H. influenzae type b (Hib) and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to phase I clinical trials in 1994. In June 2000, Chong moved to New York, NY, USA, and joined the Biotechnology Company United Biomedical Inc. (UBI) where he helped in developing a peptide-based animal foot-mouth disease vaccine for pig that is currently licensed in China. In June 2003, Chong was recruited and joined NHRI to develop and establish the Vaccine Research and Development Center (VRDC). Chong has authored over 140 original research articles and has over 80 patents filed and/or granted.
Biography Updated on 4 December 2013